TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00455026

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: remifentanil
Description: target effect site concentration during induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: target effect site concentration during induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: target effect site concentration during induction
Study: NCT03768284

Intervention type: OTHER
Intervention: Saliva or buccal sample
Description: Saliva or buccal sample

Intervention type: OTHER
Intervention: Saliva or buccal sample
Description: Saliva or buccal sample

Intervention type: OTHER
Intervention: Saliva or buccal sample
Description: Saliva or buccal sample
Study: NCT00268892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study.
Study: NCT01178164

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood sampling for biological and genetic analysis
Description: * Clinical examination~* Blood sampling for biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females.
Study: NCT01685658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous ketoprofen
Description: Patients will recieve 100 mg of ketoprofen via slow intravenous perfusion. (100mg of ketoprofen powder for injection dissolved in 100 ml injectable isotonic solution)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Description: Patients will receive 1g of paracetamol via slow intravenous perfusion. (100 ml of solution at 10mg/ml)
Study: NCT01219452

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cells
Description: Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
Study: NCT02850172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk, Eat, & Breathe
Description: 1. Walking exercise: 3 times per week, 20\~30 mins per section~2. Eat: nutritional assessment and advice weekly~3. Inspiratory muscle training: twice every day, 7 days a week, 6\~8 weeks before surgery
Study: NCT00627081

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: remifentanil
Description: dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: dosage
Study: NCT00989209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: All the patients received a one-time treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol,the total dose used per patient ranged from 15-69U, mean 37.9±5.4U.
Study: NCT02722668

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood cell infusion
Description: Both Arms: Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood cell infusion
Description: Both Arms: Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATG
Description: Arm 2: 15 mg/kg IV every 12 hours Day -6 to Day -4
Study: NCT00989209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: All the patients received a one-time treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol,the total dose used per patient ranged from 15-69U, mean 37.9±5.4U.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: myofunctional therapy
Description: All the patients were submitted to individual myofunctional therapy with the speech therapist, once a week, by four weeks.The myofunctional therapy began with isometric maneuvers for muscular elongation on the non paralyzed side, and on the paralyzed side when microsurgical reconstruction was present. It also included isotonic maneuvers to increase muscle tonus and isokinetic maneuvers to increase force on the paralyzed side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: myofunctional therapy
Description: All the patients were submitted to individual myofunctional therapy with the speech therapist, once a week, by four weeks.The myofunctional therapy began with isometric maneuvers for muscular elongation on the non paralyzed side, and on the paralyzed side when microsurgical reconstruction was present. It also included isotonic maneuvers to increase muscle tonus and isokinetic maneuvers to increase force on the paralyzed side.
Study: NCT02266719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fenestrated CMD
Description: The CMD that will be used in this IDE is structurally the same as the commercially available Zenith Fenestrated AAA Endovascular Graft.~In general, the Zenith® Fenestrated AAA Endovascular Graft is a modular system constructed of full- thickness woven polyster fabric sewn to self-expanding stainless steel z-stents with braided polyster and monofilament polypropylene sutures. In this study, fenestrated grafts with usually up to 4 fenestrations may be used.~Device implantation will be performed using standardized endosvacular techniques used in the treatment of abdominal aortic aneurysms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Type I - III TAAA
Description: Device implantation will be performed using standardized endosvacular techniques used in the treatment of abdominal aortic aneurysms. Devices will be implanted in patients with type I-III thoracic abdominal aneurysms.~The branches in this study will be constructed as internal/external cuffs, axially oriented and caudally or cranially directed, as necessary . Branch position will be determined by the anatomic location of the target vessels using a consistent craniocaudal and circumferential cuff position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arch cohort
Description: Arch branched devices may be designed using one of two configurations: (1) Zone 0 device with two inner antegrade branches for the innominate artery and the left common carotid artery with or without a retrograde left subclavian artery branch and (2) Zone 1-2 device with a single retrograde subclavian artery branch with double or triple wide scallop for the left common carotid artery. These devices are designed for a of proximal landing/fixation zone of at least 20 mm of healthy aortic segment or a previous graft.
Study: NCT02721706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIPA nutritional screening tool
Description: The new nutritional screening tool termed CIPA includes Control of food Intake, Protein, and Anthropometry (CIPA) results positive when at least one of the following parameters is met: control of food intake for 72 h \<50%, serum albumin \<3 g/dl, body mass index \<18.5 kg/m2 or mid-upper arm circumference ≤ 22.5 cm.
Study: NCT04778306

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transoral Laser Surgery
Description: Remove of the laryngeal tumour via diode laser

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transoral Laser Surgery
Description: Remove of the laryngeal tumour via diode laser
Study: NCT01629576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: economic incentive
Description: economic incentive for weight loss

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: economic incentive
Description: economic incentive for weight loss
Study: NCT04424966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: The Phase 0 study will include treatment of recurrent high-grade glioma participants with 125 mg of infigratinib 7 days prior to surgical resection. Participants with tumors demonstrating PK-response will continue treatment with the same dose continuously for 21 days in 28-day cycles after surgery.
Study: NCT05530473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: capsular tension ring
Description: To insert a capsular tension ring during the cataract surgery
Study: NCT00775528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase Delayed Release
Description: 3,000, 6,000 and 12,000 unit Lipase Capsules
Study: NCT00117741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Description: Weekly individual DBT, DBT group skills training, as needed phone calls for coaching, team meeting for psychotherapists, suboxone

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Drug Counseling
Description: Weekly individual counseling and weekly group therapy following guidelines of drug counseling treatment manual,
Study: NCT02958852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole and atorvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: Fulvestrant
Description: Fulvestrant will be used as second line treatment upon progression on first line treatment with letrozole +/- atorvastatin.
Study: NCT02775539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Patients will receive 50 to 200 mg of mirabegron once a day during 16 weeks. Dose will be titrated during the first 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02139618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl Aminolevulinate (MAL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03093935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StimRouter Neuromodulation System
Description: The StimRouter Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.
Study: NCT01657084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CDA Mask
Description: The CDA (Carbon Dioxide Accumulation) mask effectuates an increase in the inspired CO2 fraction, while allowing an adequate supply of fresh air to the patient.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CDA Mask
Description: The CDA (Carbon Dioxide Accumulation) mask effectuates an increase in the inspired CO2 fraction, while allowing an adequate supply of fresh air to the patient.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CDA Mask
Description: The CDA (Carbon Dioxide Accumulation) mask effectuates an increase in the inspired CO2 fraction, while allowing an adequate supply of fresh air to the patient.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dummy mask
Description: The dummy mask is similar in appearance to the treatment mask, but causes only a negligible change in blood gases

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dummy mask
Description: The dummy mask is similar in appearance to the treatment mask, but causes only a negligible change in blood gases

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dummy mask
Description: The dummy mask is similar in appearance to the treatment mask, but causes only a negligible change in blood gases
Study: NCT02985619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injection [Avastin] (IVB-I)
Description: 0,05ml intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 10mg/mL (IVT-II)
Description: 0,03ml intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injection [Avastin] (IVB-III)
Description: 0,05ml intravitreal injection
Study: NCT03844724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZENFlow™ Drug-eluting PTA Balloon Dilatation Catheter
Description: Digital subtraction angiography（DSA）

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Balloon Dilatation Catheter
Description: Digital subtraction angiography（DSA）
Study: NCT01976728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)
Study: NCT04025138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular tests in isometric mode
Description: Protocol for neuromuscular tests in isometric mode will be assessed by the composite of these measures :~* Voluntary maximum forces plantar flexors and knee extensors~* Electrically evoked forces~* ElectroMyoGraphic activity (EMG)~* Three-Modality Evoked Potentials (TMEPs)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular tests in isometric mode
Description: Protocol for neuromuscular tests in isometric mode will be assessed by the composite of these measures :~* Voluntary maximum forces plantar flexors and knee extensors~* Electrically evoked forces~* ElectroMyoGraphic activity (EMG)~* Three-Modality Evoked Potentials (TMEPs)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular tests in isometric mode
Description: Protocol for neuromuscular tests in isometric mode will be assessed by the composite of these measures :~* Voluntary maximum forces plantar flexors and knee extensors~* Electrically evoked forces~* ElectroMyoGraphic activity (EMG)~* Three-Modality Evoked Potentials (TMEPs)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular tests in isometric mode
Description: Protocol for neuromuscular tests in isometric mode will be assessed by the composite of these measures :~* Voluntary maximum forces plantar flexors and knee extensors~* Electrically evoked forces~* ElectroMyoGraphic activity (EMG)~* Three-Modality Evoked Potentials (TMEPs)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Measure of supraspinal activation level and cortical excitation by Transcranial Magnetic Stimulation (TMS).
Study: NCT01300637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: metformin 500 mg/pill; target dose 1500 mg/day for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical-appearing pill of placebo
Study: NCT04431934

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PROBIOTIC
Description: Participants assigned to the probiotic arm will receive 2 sachets of Vivomixx® dissolved in 50 L of warm water (according to the manufacturer indications) every 12 h orally or through a nasogastric tube (in this case the tube will be flushed with 50 mL of water after the administration). The probiotic will be started 24 h after the last dose of NAA and will be administered for 14 consecutive days. Each sachet of Vivomixx® contains a combination of 4 Lactobacillus (L. paracasei 24733, L. acidophilus 24735, L. delbrueckii ssp bulgaricus 24734, L. plantarum 24730), 3 Bifidobacteria (B. brief 24732, B. longum 24736, B. infantis 24737), and Streptococcus thermophilus 24731 at a concentration of 450 billion (45x1010) live lyophilized bacteria per sachet.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FMT REGIMEN
Description: The FMT preparation will be administered as 2 doses, once a week, of 14-17 capsules per dose. Each dose (14-17 capsules) will contain the fecal microbiota equivalent to 50 gr of stools from a healthy donor. If the patient is carrying a nasogastric tube, the content of capsules will be decapsulized (\~27 gr of powder), diluted in 50 mL of water and passed through it, followed by the administration of 50 mL of water to flush the tube. The first dose will be administered 24 h after the last dose of NAA and the second dose one week later. Whenever possible, the two doses of FMT will be originated from the same donor. According to our data done by flow cytometry and bacterial culture in three replicates, each absorbate capsule contains approximately 1.12x1010 live bacteria.
Study: NCT03221036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching-placebo IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching-placebo IV infusion
Study: NCT04083235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposomal Injection
Description: Irinotecan liposome injection is irinotecan in the form of the sucrosofate salt, encapsulated in liposomes for i.v. infusion. It is supplied in sterile, single-use vials containing 10 mL of irinotecan liposome injection at a concentration of 4.3 mg/mL free base equivalent (FBE).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin injection, USP is supplied in single-dose vials containing 50 mg, 100 mg or 200 mg of oxaliplatin as a sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: Fluorouracil injection, USP is a colorless to faint yellow, aqueous, sterile, nonpyrogenic injectable solution available in 50 mL and 100 mL pharmacy bulk package. Each mL contains 50 mg fluorouracil in water for injection, USP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin Calcium for Injection is supplied in vials ranging from 50-500 mg and available as an injectable solution or lyophilized powder for reconstitution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel is a lyophilised powder containing 100 or 250 mg of paclitaxel formulated as albumin-bound particles in single-use vials for re-constitution. Each mL of the reconstituted formulation will contain 5 mg/mL paclitaxel.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine for injection is a lyophilised powder for solution for infusion, with each single use vial containing 200 mg, 1 g or 2 g of gemcitabine.
Study: NCT01342666

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tomato consumption
Description: Daily consumption of 300g of uncooked roma tomatoes during one month.
Study: NCT04330430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-VEC
Description: The treatment schedule is based on 4 courses of intralesional T-VEC and 3 courses of intraveneous Nivolumab. T-VEC first, in order to achieve the best synergistic effect with influx of CD8+ T-cells prior to the first Nivolumab dose. T-VEC monotherapy with the dose 10\^8 PFU/mL is given every 2 weeks after 3 weeks of the first T-VEC dose (with the first dose of T-VEC 10\^6 PFU/mL to allow for seroconversion), and Nivolumab will be given every 2 weeks.
Study: NCT03355495

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy - Position Change
Description: Colonoscopy is the gold standard for detecting precancerous lesions. We are proposing that changing positions will provide better visualization for detecting such lesions. We will test our intervention of patients positioned in the Right Lateral Decubitus Position to the gold standard of Left Lateral Decubitus Positioning, hypothesizing better visualization in the right lateral decubitus position.
Study: NCT03284411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Programming
Study: NCT03155152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DECT
Description: The DECT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is imposed in a decremental fashion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIIT
Description: The HIIT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is kept constant.
Study: NCT04074148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Education Program
Description: An educational lifestyle modification program, offering 4 sessions of 30 minutes theory and 30 minutes practice each, total duration 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Education brochure
Description: An educational lifestyle modification brochure
Study: NCT04300816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Uncertainty Tolerance
Description: Participants work one-on-one with an interventionist. Treatment sessions focus on understanding the difference between the controllable and uncontrollable aspects of MS, ability to tolerate not knowing exactly what the future will hold, setting personal goals for what accepting what MS will look like, and finding ways to live in conjunction with personal values despite the MS diagnosis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional CBT
Description: Participants work one-on-one with an interventionist. Treatment sessions focus on goal setting, positive activities, identifying and challenging unhelpful thoughts, and bolstering social support.
Study: NCT02931123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lattulose and rifaximine
Study: NCT03265210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RELIEF
Description: A 9-week behavioral intervention for primary care designed to reduce depression and pain-related disability.